TY - JOUR T1 - Endemic Seasonal Coronavirus Neutralisation and COVID-19 severity JF - medRxiv DO - 10.1101/2021.09.29.21264328 SP - 2021.09.29.21264328 AU - David A. Wells AU - Diego Cantoni AU - Martin Mayora-Neto AU - Cecilia Di Genova AU - Alexander Sampson AU - Matteo Ferrari AU - George Carnell AU - Angalee Nadesalingam AU - Peter Smith AU - Andrew Chan AU - Gianmarco Raddi AU - Javier Castillo-Olivares AU - Helen Baxendale AU - Nigel Temperton AU - Jonathan L. Heeney Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/01/2021.09.29.21264328.abstract N2 - The virus SARS-CoV-2, responsible for the global COVID-19 pandemic, spread rapidly around the world causing high morbidity and mortality because humans have no pre-existing immunity. However, there are four known, endemic seasonal coronaviruses in humans (HCoVs) and whether antibodies for these HCoVs play a role in severity of COVID-19 disease has generated a lot of interest. Of these seasonal viruses NL63 is of particular interest as it uses the same cell entry receptor as SARS-CoV-2.We use functional, neutralising assays to investigate cross reactive antibodies and their relationship with COVID-19 severity. We analysed neutralisation of SARS-CoV-2, NL63, HKU1, and 229E in 38 COVID-19 patients and 62 healthcare workers, and a further 182 samples to specifically study the relationship between SARS-CoV-2 and NL63.We found that although HCoV neutralisation was very common there was little evidence that these antibodies neutralised SARS-CoV-2. Despite no evidence in cross neutralisation, levels of NL63 neutralisating antibodies become elevated after exposure to SARS-CoV-2 through infection or following vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was undertaken by the Humoral Immune Correlates to COVID-19 (HICC) consortium, funded by the UKRI and NIHR; grant number G107217 (COV0170 - HICC: Humoral Immune Correlates for COVID19). RW and SE received funding from the StMWK (ForCOVID, Bavaria, Germany)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Research Ethics Committee Wales, IRAS 96194 12/WA/0148. Amendment 5. All participants provided written and informed consent prior to being enrolled in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data would be made available upon request ER -